Key statistics
On Monday, Arcutis Biotherapeutics Inc (ARQT:NSQ) closed at 24.76, -22.06% below its 52-week high of 31.77, set on Dec 08, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 25.94 |
|---|---|
| High | 26.12 |
| Low | 24.65 |
| Bid | 24.35 |
| Offer | 25.10 |
| Previous close | 26.97 |
| Average volume | 1.71m |
|---|---|
| Shares outstanding | 124.03m |
| Free float | 121.99m |
| P/E (TTM) | -- |
| Market cap | 3.07bn USD |
| EPS (TTM) | -0.1325 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
- Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
- Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
- Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
- Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
- Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
- FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
- Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
- Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
More ▼
